Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Subcutaneous LY3832479 (Etesevimab) in Healthy Participants
NCT04611789Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LY3832479 with Placebo (2 arms). Primary endpoints: Area Under the Concentration Versus Time Curve From Time 0 to Tlast at Day 85 and Maximum Serum Concentration at Day 85. Started Nov 2020; status: completed.
02
Drugs
etesevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04611789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611789.